Manufacturing, characterization and control of cell-based medicinal products: challenging paradigms toward commercial use.
暂无分享,去创建一个
Ilona Reischl | Sol Ruiz | Dariusz Sladowski | Jean-Hugues Trouvin | I. Reischl | E. Flory | C. Schneider | A. Tsiftsoglou | J. Trouvin | P. Salmikangas | J. Borg | Paula Salmikangas | Christian K Schneider | Jan Kyselovic | Margarida Menezes-Ferreira | Asterios Tsiftsoglou | John Joseph Borg | Egbert Flory | Patrick Celis | Janis Ancans | Marcos Timon | Guido Pante | Metoda Lipnik-Stangelj | J. Kyselovič | J. Ancāns | M. Timón | P. Celis | M. Menezes-Ferreira | M. Lipnik-Štangelj | G. Pantè | S. Ruiz | D. Šladowski
[1] D. Prockop,et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.
[2] M. Suematsu,et al. Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. , 2013, Cell stem cell.
[3] P. Layrolle,et al. Pericyte-Like Progenitors Show High Immaturity and Engraftment Potential as Compared with Mesenchymal Stem Cells , 2012, PloS one.
[4] G. Pellegrini,et al. Location and Clonal Analysis of Stem Cells and Their Differentiated Progeny in the Human Ocular Surface , 1999, The Journal of cell biology.
[5] L Partington,et al. Biochemical changes caused by decellularization may compromise mechanical integrity of tracheal scaffolds. , 2013, Acta biomaterialia.
[6] Sadik H. Kassim,et al. From lipoproteins to chondrocytes: a brief summary of the European Medicines Agency's regulatory guidelines for advanced therapy medicinal products. , 2013, Human gene therapy.
[7] T. Graf,et al. Historical origins of transdifferentiation and reprogramming. , 2011, Cell stem cell.
[8] Wendell A. Lim,et al. Cell-Based Therapeutics: The Next Pillar of Medicine , 2013, Science Translational Medicine.
[9] D. Kirouac,et al. The systematic production of cells for cell therapies. , 2008, Cell stem cell.
[10] Krishanu Saha,et al. Technical challenges in using human induced pluripotent stem cells to model disease. , 2009, Cell stem cell.
[11] Elias A. Rivera,et al. Potency evaluation of tissue engineered and regenerative medicine products. , 2013, Trends in biotechnology.
[12] S. Yamanaka,et al. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.
[13] J. Thomson,et al. Embryonic stem cell lines derived from human blastocysts. , 1998, Science.
[14] Christopher A Bravery,et al. Potency assay development for cellular therapy products: an ISCT review of the requirements and experiences in the industry. , 2013, Cytotherapy.
[15] K. Tarte,et al. Risk of tumorigenicity in mesenchymal stromal cell-based therapies--bridging scientific observations and regulatory viewpoints. , 2013, Cytotherapy.
[16] M. Serrano,et al. Reprogramming in vivo produces teratomas and iPS cells with totipotency features , 2013, Nature.
[17] Ji-yeon Lee,et al. In vitro and in vivo analyses of human embryonic stem cell‐derived dopamine neurons , 2005, Journal of neurochemistry.
[18] C. Mason,et al. Bioprocess Forces and Their Impact on Cell Behavior: Implications for Bone Regeneration Therapy , 2011, Journal of tissue engineering.
[19] G. Korbutt,et al. Insulin expressing cells from differentiated embryonic stem cells are not beta cells , 2004, Diabetologia.
[20] Hemanthram Varadaraju,et al. Downstream Technology Landscape for Large-Scale Therapeutic Cell Processing , 2013 .
[21] Andrew Buchanan,et al. Clinical development of advanced therapy medicinal products in Europe: evidence that regulators must be proactive. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[22] M. Betjes,et al. Mesenchymal stromal cells for organ transplantation: different sources and unique characteristics? , 2014, Current opinion in organ transplantation.
[23] N. Benvenisty,et al. The tumorigenicity of human embryonic stem cells. , 2008, Advances in cancer research.
[24] David J Williams,et al. Concise Review: Mind the Gap: Challenges in Characterizing and Quantifying Cell- and Tissue-Based Therapies for Clinical Translation , 2010, Stem cells.
[25] D. Cyranoski. iPS cells in humans , 2013, Nature Biotechnology.
[26] M. Baker. Court lifts cloud over embryonic stem cells , 2013, Nature.
[27] J. Marchal,et al. Cardiomyogenic differentiation potential of human endothelial progenitor cells isolated from patients with myocardial infarction. , 2014, Cytotherapy.
[28] E. Jones,et al. Age-related changes in human bone marrow-derived mesenchymal stem cells: Consequences for cell therapies , 2008, Mechanisms of Ageing and Development.
[29] A. Caplan,et al. Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine , 2013, Experimental & Molecular Medicine.
[30] Canary Wharf,et al. Reflection paper on classification of advanced therapy medicinal products , 2012 .
[31] M. Neubauer,et al. Mesenchymal stromal cell characteristics vary depending on their origin. , 2013, Stem cells and development.
[32] L. Looijenga,et al. Lessons from human teratomas to guide development of safe stem cell therapies , 2012, Nature Biotechnology.